[Figures 2](#pone-0098314-g001){ref-type="fig"}, [5](#pone-0098314-g002){ref-type="fig"}, [6](#pone-0098314-g003){ref-type="fig"}, and [7](#pone-0098314-g004){ref-type="fig"} are in the incorrect order. The publisher apologizes for these errors. The figure legends are correct. The correct versions of [Figures 2](#pone-0098314-g001){ref-type="fig"}, [5](#pone-0098314-g002){ref-type="fig"}, [6](#pone-0098314-g003){ref-type="fig"}, and [7](#pone-0098314-g004){ref-type="fig"} can be viewed here.

![PKR2 antagonist reduced plasma LH levels (Mean ± S.E.).\
The LH levels in the PKR2 antagonist (10 mg/kg 3Cl-MPL) group were significantly reduced compared to the vehicle treatment (n  =  6 for each group, p\<0.01.](pone.0098314.g001){#pone-0098314-g001}

![The coexpression of PKR2 and ERα in the preoptic area. PKR2 and ERα were detected by immunofluorescence staining.\
PKR2-GFP expression was shown in green and ERα expression was shown in red. Yellow or orange color in the MnPO and AVPV regions indicates likely co-expression of PKR2 and ERα (scale bars:100 µm).](pone.0098314.g002){#pone-0098314-g002}

![Potency of PKR2 antagonist, 3Cl-MPL, in antagonizing PKR2.\
Antagonist potency was examined in Chinese Hamster Ovary (CHO) cells that stably express PKR2. RLU is an index for calcium influx measurement with a luminescence-based assay. The IC50 of 3Cl-MPL for PKR2 were 24.9±4.3 nM(Mean ± S.E.). Shown was representative of three independent experiments.](pone.0098314.g003){#pone-0098314-g003}

![Blocking of estrous cycle by PKR2 antagonist treatment.\
The administration of 3Cl-MPL (shown in red arrows) prevented the progression to estrous stage. Vehicle treatment was shown by blue arrows. E: estrus, P: proestrus, D: diestrus, M: metestrus.](pone.0098314.g004){#pone-0098314-g004}
